To: [HCP]
From: noreply@e.janssen.com
Subject line A: First-in-class treatment for EGFR exon 20 insertion mutations|RYBREVANT® mutations
Subject line B: RYBREVANT® (amivantamab-vmjw) study results
Preheader: Review the clinical data

